All In Biotech

Drug Trial Radar · NCT07203001

A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

An Open-label Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Nov 3, 2025

Primary completion

Apr 22, 2027

Study completion May 17, 2028

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 (arumakimig) in pediatric and adult participants with Still's disease

Conditions

  • Still´s Disease

Interventions

  • MAS825Drug

    Experimental drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with clinical response based on one set of response criteriaTime frame: Day 85

Locations

24 sites in 8 countries. Site status is shown where the registry gives one.

  • Cincinnati Childrens Hospital

    Cincinnati, Ohio · Active not recruiting

  • Legacy Emanuel Research Hosp Portland

    Portland, Oregon · Recruiting

  • University of Utah

    Salt Lake City, Utah · Recruiting

  • Novartis Investigative Site

    Toronto, Ontario, Canada · Recruiting

  • Novartis Investigative Site

    Montreal, Quebec, Canada · Withdrawn

  • Novartis Investigative Site

    Montreal, Quebec, Canada · Withdrawn

  • Novartis Investigative Site

    Bordeaux, France · Recruiting

  • Novartis Investigative Site

    Bron, France · Recruiting

  • Novartis Investigative Site

    Le Kremlin-Bicêtre, France · Recruiting

  • Novartis Investigative Site

    Lille, France · Recruiting

  • Novartis Investigative Site

    Paris, France · Recruiting

  • Novartis Investigative Site

    Paris, France · Recruiting

  • Novartis Investigative Site

    Heidelberg, Germany · Recruiting

  • Novartis Investigative Site

    Münster, Germany · Recruiting

  • Novartis Investigative Site

    Sankt Augustin, North Rhine-Westphalia, Germany · Recruiting

  • Novartis Investigative Site

    Florence, FI, Italy · Recruiting

  • Novartis Investigative Site

    Genova, GE, Italy · Recruiting

  • Novartis Investigative Site

    Roma, RM, Italy · Recruiting

  • Novartis Investigative Site

    Utrecht, Netherlands · Active not recruiting

  • Novartis Investigative Site

    Madrid, Spain · Recruiting

  • Novartis Investigative Site

    Valencia, Spain · Recruiting

  • Novartis Investigative Site

    Esplugues, Barcelona, Spain · Recruiting

  • Novartis Investigative Site

    Istanbul, Fatih, Turkey (Türkiye) · Recruiting

  • Novartis Investigative Site

    Ankara, Sihhiye Altindag, Turkey (Türkiye) · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.